Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
Brigham and Women's Hospital · Harvard University · +18 more institutions
Abstract
Cardiovascular-kidney-metabolic syndrome is an emerging entity that connects cardiovascular diseases, chronic kidney disease and diabetes. The non-steroidal mineralocorticoid receptor antagonist finerenone has been studied in three prospective randomized clinical trials of patients with cardiovascular-kidney-metabolic syndrome: FIDELIO-DKD, FIGARO-DKD and FINEARTS-HF. In light of the strong epidemiological overlap and shared mechanistic drivers of clinical outcomes across cardiovascular-kidney-metabolic syndrome, we summarize the efficacy and safety of finerenone on cardiovascular, kidney and mortality outcomes in this pre-specified participant-level pooled analysis. The three trials included 18,991…
Citation impact
- FWCI
- 36.02
- Percentile
- 100%
- References
- 28
Authors
23- MVMuthiah VaduganathanCorresponding
Brigham and Women's Hospital, Harvard University
- GFGerasimos Filippatos
National and Kapodistrian University of Athens
- BCBrian Claggett
Brigham and Women's Hospital, Harvard University
- ASAkshay S. Desai
Brigham and Women's Hospital, Harvard University
- PSPardeep S. Jhund
University of Glasgow
Topics & keywords
- Medicine
- Heart failure
- Kidney disease
- Type 2 diabetes
- Diabetes mellitus
- Internal medicine
- Cardiology
- Disease
- Good health and well-being